首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   90461篇
  免费   10897篇
  国内免费   190篇
耳鼻咽喉   1372篇
儿科学   2701篇
妇产科学   2007篇
基础医学   12109篇
口腔科学   2117篇
临床医学   11375篇
内科学   16708篇
皮肤病学   1717篇
神经病学   7553篇
特种医学   3192篇
外国民族医学   10篇
外科学   13699篇
综合类   1686篇
一般理论   67篇
预防医学   10093篇
眼科学   2533篇
药学   6857篇
  1篇
中国医学   81篇
肿瘤学   5670篇
  2023年   999篇
  2021年   1384篇
  2020年   1132篇
  2019年   1299篇
  2018年   2042篇
  2017年   1718篇
  2016年   1715篇
  2015年   1834篇
  2014年   2410篇
  2013年   3307篇
  2012年   3840篇
  2011年   4083篇
  2010年   2494篇
  2009年   2578篇
  2008年   3554篇
  2007年   3731篇
  2006年   3642篇
  2005年   3646篇
  2004年   3386篇
  2003年   3127篇
  2002年   3063篇
  2001年   2850篇
  2000年   2896篇
  1999年   2605篇
  1998年   1159篇
  1997年   970篇
  1996年   937篇
  1995年   844篇
  1994年   856篇
  1993年   769篇
  1992年   2155篇
  1991年   2084篇
  1990年   1941篇
  1989年   1897篇
  1988年   1806篇
  1987年   1807篇
  1986年   1697篇
  1985年   1683篇
  1984年   1403篇
  1983年   1282篇
  1982年   866篇
  1981年   736篇
  1979年   1234篇
  1978年   884篇
  1977年   765篇
  1976年   719篇
  1975年   725篇
  1974年   868篇
  1973年   774篇
  1972年   741篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
22.
23.
24.
25.
26.

Background

We have recently shown that human epididymis protein 4 (HE4) levels correlate with the severity of cystic fibrosis (CF) lung disease. However, there are no data on how HE4 levels alter in patients receiving CFTR modulating therapy.

Methods

In this retrospective clinical study, 3 independent CF patient cohorts (US-American: 29, Australian: 12 and Irish: 19 cases) were enrolled carrying at least one Class III CFTR CF-causing mutation (p.Gly551Asp) and being treated with CFTR potentiator ivacaftor. Plasma HE4 was measured by immunoassay before treatment (baseline) and 1–6?months after commencement of ivacaftor, and were correlated with FEV1 (% predicted), sweat chloride, C-reactive protein (CRP) and body mass index (BMI).

Results

After 1?month of therapy, HE4 levels were significantly lower than at baseline and remained decreased up to 6?months. A significant inverse correlation between absolute and delta values of HE4 and FEV1 (r?=??0.5376; P?<?.001 and r?=??0.3285; P?<?.001), was retrospectively observed in pooled groups, including an independent association of HE4 with FEV1 by multiple regression analysis (β?=??0.57, P?=?.019). Substantial area under the receiver operating characteristic curve (ROC-AUC) value was determined for HE4 when 7% mean change of FEV1 (0.722 [95% CI 0.581–0.863]; P?=?.029) were used as classifier, especially in the first 2?months of treatment (0.806 [95% CI 0.665–0.947]; P?<?.001).

Conclusions

This study shows that plasma HE4 levels inversely correlate with lung function improvement in CF patients receiving ivacaftor. Overall, this potential biomarker may be of value for routine clinical and laboratory follow-up of CFTR modulating therapy.  相似文献   
27.
28.
HOCK LEONG EE  MBBS  MRCP    CHEE LEOK GOH  MBBS  FRCP    KHOO    ES-Y. CHAN  PHD    POR ANG  MBBS  MRCP 《Dermatologic surgery》2006,32(1):34-40
BACKGROUND: Acquired bilateral nevus of Ota-like macules (Hori's nevus) is a common dyschromatosis among Asian women. Q-switched lasers have been used successfully as a treatment modality. OBJECTIVE: The purpose of this study was to compare the efficacy of using the Q-switched 532 nm neodymium:yttrium-aluminum-garnet (Nd:YAG) laser followed by the 1,064 nm laser versus the Q-switched 1,064 nm Nd:YAG laser alone in the treatment of Hori's nevus. METHODS: This is a prospective left-right comparative study. Ten women with bilateral Hori's nevus were recruited and treated with a combination of the Q-switched 532 and 1,064 nm Nd:YAG lasers on the right cheek and the Q-switched 1,064 nm Nd:YAG laser alone on the left cheek. Only one laser treatment session was performed. The degree of pigmentation was objectively recorded with a mexameter. Subjective assessment was made by both patients and two blinded, nontreating dermatologists. RESULTS: At 6 months, there was a statistically significant difference (p = .009) of 35.10 points using objective mexameter measurements between the two sides, favoring the side treated with a combination of 532 and 1,064 nm laser treatment. Subjective grading by the patients and blinded dermatologists also confirmed that combination therapy was more successful after one treatment. Although combination treatment had a higher incidence of mild postinflammatory changes, this disappeared within 2 months. CONCLUSIONS: Concurrent use of the Q-switched 532 nm Nd:YAG laser in combination with the 1,064 nm laser is more effective in pigment clearance than the Q-switched 1,064 nm Nd:YAG laser alone for Hori's nevi.  相似文献   
29.
Toby O. Smith   《Physiotherapy》2006,92(3):135-145
Pretibial lacerations and lower limb wounds are referred to plastic surgery teams for split skin graft surgery. Traditionally, these patients have been immobilised on bedrest following surgery. More recently, patients have commenced ambulation earlier to avoid medical complications and facilitate discharge. The objective of this literature review was to determine when such patients should begin walking. A literature search was undertaken using the electronic databases AMED, Cinahl, Embase, Medline (via Ovid), PEDro and Pubmed. Clinical trials using human subjects, written in English, were included. Seventeen (of 1137) papers met the inclusion criteria and were reviewed. The literature suggested that patients should begin walking immediately or at the earliest possible opportunity after lower limb skin graft surgery. Although the literature advocated early ambulation, the evidence base presented with a number of recurrent methodological limitations, including small sample sizes, lack of a control sample, and limited follow-up. Accordingly, further research employing large, well-designed, randomised controlled trials is recommended. It will then be possible to understand with greater certainty when patients should begin walking after lower extremity split skin graft surgery.  相似文献   
30.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号